{"analyses":[{"ciLowerLimit":"0.53","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.87","groupDescription":"Analysis performed using a stratified log rank test adjusting for age at randomization (\\<65 vs ≥65), sex (male vs female), and smoking history (smoker vs non-smoker) with ties handled using the Breslow approach.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.00251","paramType":"Hazard Ratio (HR)","paramValue":"0.68","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median and upper limit of 95% confidence interval (CI) could not be calculated as they were not reached.","groupId":"OG000","lowerLimit":"34.7","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% CI could not be calculated as it was not reached.","groupId":"OG001","lowerLimit":"22.9","upperLimit":"NA","value":"28.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization until death due to any cause. OS was calculated using the Kaplan-Meier technique.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients in the durvalumab (MEDI4736) monotherapy group were to receive durvalumab 10 mg/kg Q2W via intravenous infusion for up to 12 months.","id":"OG000","title":"Durvalumab (MEDI4736)"},{"description":"Patients in the placebo group were to receive matching placebo for intravenous infusion Q2W for up to 12 months.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized patients, analyzed on an ITT basis.","reportingStatus":"POSTED","timeFrame":"From baseline until death due to any cause. Assessed until 22 Mar 2018 DCO; up to a maximum of approximately 4 years.","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Months"}